Last reviewed · How we verify

Sayana Press

FHI 360 · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Sayana Press is a Small molecule drug developed by FHI 360. It is currently FDA-approved. Also known as: medroxyprogesterone acetate (MPA) injectable suspension, depot medroxyprogesterone acetate (DMPA).

Sayana Press is a subcutaneous formulation of medroxyprogesterone acetate (MPA), a progesterone receptor agonist. It is used for contraception and has been studied in clinical trials for various indications, including HIV infections and drug-drug interactions.

At a glance

Generic nameSayana Press
Also known asmedroxyprogesterone acetate (MPA) injectable suspension, depot medroxyprogesterone acetate (DMPA)
SponsorFHI 360
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sayana Press

What is Sayana Press?

Sayana Press is a Small molecule drug developed by FHI 360.

Who makes Sayana Press?

Sayana Press is developed and marketed by FHI 360 (see full FHI 360 pipeline at /company/fhi-360).

Is Sayana Press also known as anything else?

Sayana Press is also known as medroxyprogesterone acetate (MPA) injectable suspension, depot medroxyprogesterone acetate (DMPA).

What development phase is Sayana Press in?

Sayana Press is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing